Cynata Therapeutics Limited
ASX: CYP.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kilian Kelly
- Headquarters
- Cremorne, Australia
- IPO year
- 2007
- Market cap
- A$79.5M
- Website
- https://www.cynata.com
Loading CYP…
Loading profile data…Frequently asked questions about CYP
What does Cynata Therapeutics Limited (CYP.AX) do?
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host dise...
Where does CYP.AX trade?
Cynata Therapeutics Limited (CYP.AX) trades on the Australian Securities Exchange.
What sector is CYP.AX in?
Cynata Therapeutics Limited (CYP.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cynata Therapeutics Limited?
Kilian Kelly is the chief executive officer of Cynata Therapeutics Limited (CYP.AX).
Where is Cynata Therapeutics Limited headquartered?
Cynata Therapeutics Limited is headquartered in Australia.
Does CYP.AX pay a dividend?
Cynata Therapeutics Limited (CYP.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYP.AX go public?
Cynata Therapeutics Limited (CYP.AX) completed its initial public offering in 2007.